Fig 1.

Kaplan–Meier curves for recurrence-specific survival for patients who did (purple) or did not (blue) receive ketorolac, for (a) all patients in the cohort, (b) patients with nuclear factor erythroid 2-related factor 2 (NRF2) oncogenic pathway alteration, and (c) patients with MDM2 gene alteration. (d) Predicted pro-vs antitumour regulation by ketorolac of the six survival-associated gene networks in The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) external validation cohort; each row corresponds to one survival-associated gene network, and the coloured circle represents ketorolac's strength and direction (pro-vs antitumour) of regulation of that network in comparison with all 8558 other drugs and small molecules in the Connectivity Map database, given as a percentile rank (tau), where the purple dotted line represents the 50th percentile and the blue dotted line represents the 90th percentile. (e) Survival curves for patients in the TCGA-LUAD cohort with up-vs downregulation of the survival-associated gene network highlighted by the blue circle in (d). (f) Predicted antitumour regulation by ketorolac of the highlighted gene network (x-axis tau, as described previously), with other drugs commonly used in the treatment of lung adenocarcinoma highlighted for comparison.